

WEDNESDAY 2nd April 2014 COMMENCING 10.30 AM
AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

- | | |
|--|-----------------------------------|
| 1. Welcome and introduction | Enclosure |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0414 |
| 5. Chairman's report (verbal update) | |
| 6. Appraisal 1 – Limited submission
Darunavir (Prezista[®]) 400 mg, 800 mg tablets and 100 mg/ml oral suspension co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in paediatric patients from the age of 12 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naive; or ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4 ⁺ cell count ≥ 100 cells x 10 ⁶ /l. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir | 2/AWMSG/0414
Appendices |
| 7. National Prescribing Indicators 2014–2015: Supporting Information for Prescribers | 3/AWMSG/0414 |
| 8. National Prescribing Indicators: Analysis of Yellow Card Reporting Data to December 2013 | 4/AWMSG/0414 |
| 9. Monitoring of Medicines Appraised by NICE and AWMSG: Summary | 5/AWMSG/0414 |
| 10. Mental Health & Medication Wales | 6/AWMSG/0414 |

Date of next meeting:
Wednesday 7th May 2014 in Abergavenny